Marker Therapeutics, Inc.
No enriched coverage for $MRKR in the last 7 days.
No SEC Form 4 filings for $MRKR in the last 30 days.
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing ( MAR ) T cells as an Off-the-Shelf ( OTS ) product to accelerate time to treatment ...
MT-601 shows a 66% response rate in NHL patients, with 50% achieving a complete response. No dose-limiting toxicities or serious adverse events were reported in the Phase 1 trial. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here → Marker Therapeutics, ...
